Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Pomalidomide by Qilu Pharmaceutical for Refractory Multiple Myeloma: Likelihood of Approval
Pomalidomide is under clinical development by Qilu Pharmaceutical and currently in Phase III for Refractory Multiple Myeloma. According to GlobalData,...
Pomalidomide by Bristol-Myers Squibb for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Pomalidomide is under clinical development by Bristol-Myers Squibb and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Pomalidomide by Bristol-Myers Squibb for Glioblastoma Multiforme (GBM): Likelihood of Approval
Pomalidomide is under clinical development by Bristol-Myers Squibb and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...